Treatment of Lateral Epicondylitis With Platelet-Rich Plasma, Glucocorticoid, or Saline A Randomized, Double-Blind, Placebo-Controlled Trial

被引:231
|
作者
Krogh, Thoger Persson [1 ]
Fredberg, Ulrich [1 ]
Stengaard-Pedersen, Kristian [1 ]
Christensen, Robin [1 ]
Jensen, Pia [1 ]
Ellingsen, Torkell [1 ]
机构
[1] Reg Hosp Silkeborg, Ctr Diagnost, DK-8600 Silkeborg, Denmark
来源
AMERICAN JOURNAL OF SPORTS MEDICINE | 2013年 / 41卷 / 03期
关键词
lateral humeral epicondylitis; tendinopathy; growth factors; platelet-rich plasma; glucocorticoid; ultrasonography; injection therapy; pain; randomized controlled trial; POWER DOPPLER ULTRASOUND; UPPER-LIMB DISORDERS; CHRONIC TENNIS ELBOW; CORTICOSTEROID INJECTION; MEDIAL EPICONDYLITIS; SPORTS-MEDICINE; CLINICAL-TRIAL; TENDON REPAIR; BASE-LINE; FOLLOW-UP;
D O I
10.1177/0363546512472975
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Lateral epicondylitis (LE) is a common musculoskeletal disorder for which an effective treatment strategy remains unknown. Purpose: To examine whether a single injection of platelet-rich plasma (PRP) is more effective than placebo (saline) or glucocorticoid in reducing pain in adults with LE after 3 months. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: A total of 60 patients with chronic LE were randomized (1: 1: 1) to receive either a blinded injection of PRP, saline, or glucocorticoid. The primary end point was a change in pain using the Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire at 3 months. Secondary outcomes were ultrasonographic changes in tendon thickness and color Doppler activity. Results: Pain reduction at 3 months (primary end point) was observed in all 3 groups, with no statistically significant difference between the groups; mean differences were the following: glucocorticoid versus saline: -3.8 (95% CI, -9.9 to 2.4); PRP versus saline: -2.7 (95% CI, -8.8 to 3.5); and glucocorticoid versus PRP: -1.1 (95% CI, -7.2 to 5.0). At 1 month, however, glucocorticoid reduced pain more effectively than did both saline and PRP; mean differences were the following: glucocorticoid versus saline: -8.1 (95% CI, -14.3 to -1.9); and glucocorticoid versus PRP: -9.3 (95% CI, -15.4 to -3.2). Among the secondary outcomes, at 3 months, glucocorticoid was more effective than PRP and saline in reducing color Doppler activity and tendon thickness. For color Doppler activity, mean differences were the following: glucocorticoid versus PRP: -2.6 (95% CI, -3.1 to -2.2); and glucocorticoid versus saline: -2.0 (95% CI, -2.5 to -1.6). For tendon thickness, mean differences were the following: glucocorticoid versus PRP: -0.5 (95% CI, -0.8 to -0.2); and glucocorticoid versus saline: -0.8 (95% CI, -1.2 to -0.5). Conclusion: Neither injection of PRP nor glucocorticoid was superior to saline with regard to pain reduction in LE at the primary end point at 3 months. However, injection of glucocorticoid had a short-term pain-reducing effect at 1 month in contrast to the other therapies. Injection of glucocorticoid in LE reduces both color Doppler activity and tendon thickness compared with PRP and saline.
引用
收藏
页码:625 / 635
页数:11
相关论文
共 50 条
  • [1] TREATMENT OF LATERAL EPICONDYLITIS WITH INJECTION OF PLATELET-RICH PLASMA OR CORTICOSTEROID VERSUS SALINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Krogh, T.
    Fredberg, U.
    Stengaard-Pedersen, K.
    Christensen, R.
    Ellingsen, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 620 - 620
  • [2] Treatment of Lateral Epicondylitis with Injection of Platelet-Rich Plasma or Corticosteroid Versus Saline: A Randomized, Double-Blind, Placebo-Controlled Trial
    Krogh, Thoger
    Fredberg, Ulrich
    Stengaard-Pedersen, Kristian
    Jensen, Pia
    Christensen, Robin
    Ellingsen, Torkell
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S415 - S416
  • [3] PLATELET-RICH PLASMA AND PLASMA FOR TREATMENT OF KNEE OSTEOARTHRITIS: A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL
    Dorio, M.
    Pereira, R. M.
    Oliveira, R. M.
    Luz, A. G.
    Fuller, R.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 : S481 - S482
  • [4] The Addition of Platelet-Rich Plasma to Facial Lipofilling: A Double-Blind, Placebo-Controlled, Randomized Trial
    Ozer, Kadri
    Atan, Oguz
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2018, 142 (05) : 795E - 796E
  • [5] The Addition of Platelet-Rich Plasma to Facial Lipofilling: A Double-Blind, Placebo-Controlled, Randomized Trial
    Willemsen, Joep C. N.
    Van Dongen, Joris
    Spiekman, Maroesjka
    Vermeulen, Karin M.
    Harmsen, Martin C.
    van der Lei, Berend
    Stevens, H. P. Jeroen
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2018, 141 (02) : 331 - 343
  • [6] Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
    Masterson, Thomas A.
    Molina, Manuel
    Ledesma, Braian
    Zucker, Isaac
    Saltzman, Russell
    Ibrahim, Emad
    Han, Sunwoo
    Reis, Isildinha M.
    Ramasamy, Ranjith
    JOURNAL OF UROLOGY, 2023, 210 (01): : 154 - 161
  • [7] Reply: The Addition of Platelet-Rich Plasma to Facial Lipofilling: A Double-Blind, Placebo-Controlled, Randomized Trial
    van Dongen, Joris A.
    Willemsen, Joep C. N.
    Spiekman, Maroesjka
    Vermeulen, Karin M.
    Harmsen, Martin C.
    Stevens, Hieronymus P.
    van der Lei, Berend
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2018, 142 (05) : 796E - 798E
  • [8] Re: Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
    Fode, Mikkel
    Jensen, Christian Fuglesang S.
    Sonksen, Jens
    EUROPEAN UROLOGY, 2024, 85 (01) : 93 - 93
  • [9] Treatment of lateral epicondylitis with botulinum toxin. A randomized, double-blind, placebo-controlled trial
    Wong, SM
    Hui, ACF
    Tong, PY
    Poon, DWF
    Yu, E
    Wong, LKS
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (11) : 793 - 797
  • [10] PLATELET-RICH PLASMA (PRP) IMPROVES ERECTILE FUNCTION: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
    Poulios, E.
    Mykoniatis, I
    Pyrgidis, N.
    Zilotis, F.
    Kapoteli, V
    Kotsiris, D.
    Kalyvianakis, D.
    Hatzichristou, D.
    JOURNAL OF SEXUAL MEDICINE, 2022, 19 (05): : S157 - S158